GSK raises £1.25bn from sale of remaining Haleon stake
17th May 2024 07:29
(Sharecast News) - GSK said on Friday that it has sold its remaining 4.2% stake in consumer health business Haleon, which it spun off in July 2022.
Read moreGSK to sell entire 4.2% remaining stake in Haleon
16th May 2024 17:02
(Sharecast News) - GSK said on Thursday that it plans to sell its entire remaining 4.2% stake in Haleon.
Read moreLondon close: Stocks mixed as ex-divs drag on FTSE
16th May 2024 16:53
(Sharecast News) - London stocks ended mixed on Thursday, following a flurry of corporate news and a focus on US unemployment figures.
Read moreLondon close: Stocks fall ahead of US Fed decision
1st May 2024 16:42
(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.
Read moreGSK lifts annual guidance on strong virus treatment sales
1st May 2024 07:36
(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.
Read moreGSK's endometrial cancer drug receives FDA approval
24th Apr 2024 09:21
(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Jemperli, its drug aimed at treating endometrial cancer.
Read moreGSK posts promising results from gonorrhoea treatment trial
17th Apr 2024 07:11
(Sharecast News) - GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid escalating resistance to current therapies.
Read moreGSK meningococcal vaccine accepted by US FDA for review
16th Apr 2024 09:17
(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).
Read moreGSK unveils promising results from endometrial cancer trial
18th Mar 2024 12:00
(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.
Read moreGSK reports more encouraging trial results for Blenrep
7th Mar 2024 07:21
(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.
Read moreGSK's ViiV upbeat on ultra-long-acting HIV treatment study
5th Mar 2024 07:26
(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).
Read moreGSK reaches settlement in another Zantac case
29th Feb 2024 07:22
(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.
Read moreGSK reports positive results from gonorrhoea treatment trial
26th Feb 2024 07:22
(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.
Read moreGSK's ViiV sees success in latest HIV treatment trial
21st Feb 2024 07:22
(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.
Read moreBerenberg hikes target price on GSK
15th Feb 2024 11:02
(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.
Read more